Literature DB >> 23637037

Sickle cell disease related mortality in the United States (1999-2009).

Dima Hamideh1, Ofelia Alvarez.   

Abstract

BACKGROUND: Little is known about the national outcome of children and adults with sickle cell disease (SCD) given contemporary care. PROCEDURE: We investigated the number of deaths, standardized crude and age-adjusted mortality rates, and causes of death among individuals with SCD across the United States during 1999-2009 according to death certificates by using a publicly available website (http://wonder.cdc.gov/). Data were compared to mortality during 1979-1998.
RESULTS: When compared to 1979-1998, mortality significantly decreased by 61% in infants <1 year of age, by 67% in children aged 1-4 years, and by 22-35% in children aged 5-19 years. After 19 years of age, mortality rates increased from 0.6 in the 15-19 year group to 1.4/100,000 in the 20-24 year group, corresponding to the transition period from pediatric to adult medical care, and this increase was similar during 1979-1998. Although the age groups with the highest mortality were 35-44 years for males and 45-54 years for females, there was a tendency for longer survival because there were more deaths among those individuals 55-74 years of age compared to previous years. For all individuals, the causes of deaths were cardiac disease (31.6%), respiratory (28.1%), renal (16.4%), infectious (14.4%), neurologic (11.9%), and gastrointestinal and hepatobiliary (9.2%) in nature. Cancer was the cause of death in <1%.
CONCLUSION: Mortality during childhood has decreased significantly. However, the transition period from pediatric to adult care is critical. Risk-reduction, monitoring, and early treatment intervention of cardiovascular disease in adults is warranted.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  mortality; sickle cell disease; survival; transition

Mesh:

Year:  2013        PMID: 23637037     DOI: 10.1002/pbc.24557

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  79 in total

1.  Psychometric Properties of the Psychosocial Assessment Tool-General in Adolescents and Young Adults With Sickle Cell Disease.

Authors:  Lori E Crosby; Naomi E Joffe; Nina Reynolds; James L Peugh; Ellen Manegold; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-08-13

2.  Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years.

Authors:  Agatha M Gallo; Diana J Wilkie; Yingwei Yao; Robert E Molokie; Christiane Stahl; Patricia E Hershberger; Zhongsheng Zhao; Marie L Suarez; Bonnye Johnson; Rigoberto Angulo; Jesus Carrasco; Veronica Angulo; Alexis A Thompson
Journal:  J Genet Couns       Date:  2015-08-28       Impact factor: 2.537

Review 3.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

4.  Assessing Disease Knowledge and Self-Management in Youth With Sickle Cell Disease Prior to Transition.

Authors:  Barbara Speller-Brown; Maureen Varty; Lisa Thaniel; Marni B Jacobs
Journal:  J Pediatr Oncol Nurs       Date:  2018-12-19       Impact factor: 1.636

5.  [Hemoglobin disorders].

Authors:  R Dickerhoff
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

6.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

7.  Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Authors:  Arlene Smaldone; Deepa Manwani; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2019-04-02       Impact factor: 3.167

8.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14

9.  Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Authors:  Susan T Paulukonis; James R Eckman; Angela B Snyder; Ward Hagar; Lisa B Feuchtbaum; Mei Zhou; Althea M Grant; Mary M Hulihan
Journal:  Public Health Rep       Date:  2016 Mar-Apr       Impact factor: 2.792

10.  Patterns of opioid use in sickle cell disease.

Authors:  Jin Han; Santosh L Saraf; Xu Zhang; Michel Gowhari; Robert E Molokie; Joharah Hassan; Chaher Alhandalous; Shivi Jain; Jewel Younge; Taimur Abbasi; Roberto F Machado; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2016-08-08       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.